AI Article Synopsis
- Researchers studied acid and neutral beta-galactosidases from the intestinal mucosa of suckling rats, finding their characteristics and behaviors.
- The acid beta-galactosidase had a molecular weight between 83,000-105,000, while the neutral type was significantly larger at 360,000-510,000.
- Both enzymes showed competitive inhibition by certain compounds, with distinct K(i) values, and were inactivated by heat and urea, with the neutral enzyme being more sensitive.
- No differences in enzyme properties were observed between the jejunum and ileum samples.
Article Abstract
1. The characteristics of acid and neutral beta-galactosidases isolated chromatographically from homogenates of the mucosa of the jejunum and ileum of suckling rats were studied. 2. The minimal molecular weight of the acid beta-galactosidase, as estimated by gel filtration on Sephadex G-200, was in the range 83000-105000, whereas for the neutral beta-galactosidase the estimated molecular weight was in the range 360000-510000. 3. The acid and neutral beta-galactosidases were inhibited competitively by galactono-(1-->4)-lactone, with respective K(i) values of 0.15mm and 1.1mm. Only the acid beta-galactosidase was inhibited competitively by sodium galactonate (K(i) 0.17mm). 4. Heat inactivation of both beta-galactosidases occurred according to first-order kinetics. The neutral enzyme was more labile, but bovine serum albumin protected acid enzyme only. 5. Urea treatment inactivated both beta-galactosidases, the neutral beta-galactosidase being more sensitive than the acid beta-galactosidase. 6. No differences were found between preparations from the jejunum and ileum.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1184935 | PMC |
| http://dx.doi.org/10.1042/bj1140621 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The development of a broad-spectrum retaining β-exo-galactosidase activity-based probe.
Org Biomol Chem
October 2023
Department of Medical Biochemistry, Leiden Institute of Chemistry, Leiden University, P. O. Box 9502, 2300 RA Leiden, The Netherlands.
Acid β-galactosidase (GLB1) and galactocerebrosidase (GALC) are retaining exo-β-galactosidases involved in lysosomal glycoconjugate metabolism. Deficiency of GLB1 may result in the lysosomal storage disorders GM1 gangliosidosis, Morquio B syndrome, and galactosialidosis, and deficiency of GALC may result in Krabbe disease. Activity-based protein profiling (ABPP) is a powerful technique to assess the activity of retaining glycosidases in relation to health and disease.
View Article and Find Full Text PDFAAVrh10 vector corrects pathology in animal models of GM1 gangliosidosis and achieves widespread distribution in the CNS of nonhuman primates.
Mol Ther Methods Clin Dev
December 2022
Lysogene, 18-20 rue Jacques Dulud, 92200 Neuilly-sur-Seine, France.
GM1 gangliosidosis is a rare, inherited neurodegenerative disorder caused by mutations in the GLB1 gene, which encodes the lysosomal hydrolase acid β-galactosidase (β-gal). β-gal deficiency leads to toxic accumulation of GM1 ganglioside, predominantly in the central nervous system (CNS), resulting in progressive neurodegeneration. LYS-GM101 is an AAVrh.
View Article and Find Full Text PDFCarrier Rate and Mutant Allele Frequency of GM1 Gangliosidosis in Miniature Shiba Inus (Mame Shiba): Population Screening of Breeding Dogs in Japan.
Animals (Basel)
May 2022
Laboratory of Clinical Pathology, Joint Faculty of Veterinary Medicine, Kagoshima 890-0065, Japan.
GM1 gangliosidosis is a progressive, recessive, autosomal, neurodegenerative, lysosomal storage disorder that affects the brain and multiple systemic organs due to an acid β-galactosidase deficiency encoded by the gene. This disease occurs in the Shiba Inu breed, which is one of the most popular traditional breeds in Japan, due to the :c.1649delC (p.
View Article and Find Full Text PDFReal-time MR tracking of AAV gene therapy with βgal-responsive MR probe in a murine model of GM1-gangliosidosis.
Mol Ther Methods Clin Dev
December 2021
Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Transformative results of adeno-associated virus (AAV) gene therapy in patients with spinal muscular atrophy and Leber's congenital amaurosis led to approval of the first two AAV products in the United States to treat these diseases. These extraordinary results led to a dramatic increase in the number and type of AAV gene-therapy programs. However, the field lacks non-invasive means to assess levels and duration of therapeutic protein function in patients.
View Article and Find Full Text PDFEstablishment and characterization of breast cancer organoids from a patient with mammary Paget's disease.
Cancer Cell Int
August 2020
Department of Oncology & Department of Breast Surgery, The Second Hospital of Dalian Medical University, Dalian, 116023 China.
Background: Mammary Paget's disease (MPD) is an uncommon cutaneous intraepithelial malignancy with ulceration of the nipple or areola. Its pathogenesis and genomic mutation remain largely unknown and no cell lines are established from primary tumors.
Methods: We collected surgical tumor specimens from a 65-year-old Chinese woman diagnosed with MPD and established patient-derived breast cancer (BC) organoids from MPD using organoid culture technology.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!